DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences
Brings decentralized, in-house DNA synthesis capabilities to researchers in a rapidly growing biotechnology market
EpilepsyGTx partners with ClearPoint Neuro to support targeted delivery of lead gene therapy in epilepsy
ClearPoint Neuro’s system enables precise delivery to the seizure focus, ensuring best possible efficacy and safety of EpilepsyGTx’s investigational gene therapyPartnership will support first-in-human Phase 1/2a clinical trials of EPY201 in patients with focal refractor
DDW introduces new series of events aimed at connecting innovation with investment in early-stage drug discovery
Three-part event series will comprise a digital forum (30th September 2026), and two in-person events (London, UK, 4th November 2026, and Basel, Switzerland, March 2027)Focused on technology, innovation, and investment in early-stage drug discovery
Eppendorf Focuses Outreach Programmes to Advance STEM Education in Europe
Hamburg, DE, 07 JULY 2026 – Eppendorf, a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world, today highlights its European outreach activities dedicated to address
Bio-Rad Launches Vericheck ddPCR Kits Compatible with QX700 Platform for Biopharma Quality Control and Cell and Gene Therapy Workflows
New Vericheck ddPCR™ Kits Combine Highly Specific and Highly Sensitive DNA Detection and Quantification with the QX700™ System’s Seven-Color Multiplexing, Simplified Workflow, and Scalable Throughput
Exonate appoints Olav Hellebø as Chief Executive Officer
Appointment of experienced executive forms part of the Company’s strategy to build momentum across its proprietary platform and therapeutic programs targeting retinal diseasesCompany is preparing a Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disea
Tecan accelerates Data-Driven Lab journey with Agentic AI developments powered by NVIDIA
Männedorf, Switzerland, June 24, 2026: Tecan (SIX Swiss Exchange: TECN), a global provider of laboratory automation and solutions, today announced the integration of Agentic AI capabilities into its lab analytics platform Introspect, leveraging
FairJourney Bio and AbTherx Partner to Offer Fully Integrated Antibody Discovery
FairJourney Bio brings AbTherx’s Atlas transgenic mouse technologies in-house, enabling partner programmes to run from immunisation to a developability-assessed lead in one continuous workflowPartnership announced at BIO International Convention 2026, as FairJourney Bio
TRIMTECH Therapeutics brings total seed round to $47M with additional investment of $14M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio
Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.
Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802
US FDA clearance enables first-in-human study of PTD802, a selective GPR17 antagonist Small molecule therapeutic designed to promote remyelination in neurological diseases such as multiple sclerosis Milestone supports Pheno Therapeutics’ clin
Broken String Biosciences appoints Bruce Eaton PhD as Chairman of the Board
Strengthens Board with experienced industry executive, specializing in strategic planning, organizational leadership and commercial execution
Laverock Therapeutics reports key oncology research milestones
London, UK, 10 June 2026: Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo functional milestones across its T-cell and macrophage
PhoreMost announces lead oncology programme and appoints Chief Medical Officer to support clinical entry
Next-generation small molecule microtubule targeting agent, PMC-001, progressing towards Phase 1Comprehensive preclinical data package demonstrates differentiating oral activity and CNS penetration, unlocking treatment of primary and secondary brain cancers
Bio-Rad receives microVal validation for EZ-CheckTM Listeria spp. and EZ-Check Listeria monocytogenes Testing Kits
Methods Certified by MicroVal for Detection of Listeria spp. and Listeria monocytogenes in Food and Environmental Samples
Diagnostics start-up LotusDx establishes R&D laboratory at ONE BioHub to advance at-home STI testing
Dedicated R&D space to accelerate development of at-home testing to provide discreet, simple and fast solutions for sexually transmitted infectionsONE BioHub’s location and connectivity will facilitate ongoing clinical engagement with NHS Grampian and wider innovati
Laverock Therapeutics awarded in excess of £2.2M through two innovation grants to support AI-powered platform development and to expand therapeutic programmes outside of oncology
Grants totalling in excess of £2.2M awarded from two industry leading innovation fundsThe new grants will support the development of Laverock’s single-cell and AI powered gene-control platform, alongside pipeline expansion into additional therapeutic areas.
Combat Medical highlights patient impact of HIVEC HEAT trial at the American Urological Association Annual Meeting
MHRA-approved phase 3 study is investigating intravesical delivery of hyperthermic chemotherapy in bladder-sparing treatment of patients with non-muscle invasive bladder cancerStudy being conducted across 25 sites in the UK is designed to support FDA registration
SLAS celebrates innovative new products, startups and scientific excellence at European conference in Vienna
SLAS Celebrates Innovative New Products, Startups and Scientific Excellence at European Conference in Vienna
Tecan establishes direct sales and specialist lab automation service operations in India
Strengthening local presence and customer support in a high-growth life sciences market
OutSee selected for Discovery Award from Longitude Prize on ALS to accelerate AI-based target discovery
Funding to identify novel targets for ALS treatment using OutSee’s ‘genomics first’ target discovery platform, NomalyProvides access to world’s largest and most comprehensive ALS patient datasetPart of £7.5M global challenge prize to leverage innovatio
Cyclana Bio granted Health Research Authority approval and recruits first patients for clinical observational study in endometriosis
UK NHS grants HRA/REC approval for PEMP study with Peterborough and Cambridge hospitalsClinical observational study investigating underlying biology of endometriosis aims to uncover causal mechanisms and new druggable targets to improve treatment outcomes
Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis
Qureight’s AI-powered quantitative imaging analytics platform and services to analyse HRCT images to evaluate changes in compartment-specific lung biomarkersThe focus of these efforts will be on the quantitative assessment of change from baseline in lung fibrosis
Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001
First investigational inhaled ENaC blocker to deliver clinically relevant and statistically significant change in lung function compared to placebo Inhaled therapeutic designed to treat the 10% of people with cystic fibrosis with the highest unmet medical need
Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage
FREEDOM study to evaluate progesterone delivery using Callavid intravaginal platformNIHR-funded trial in collaboration with University Hospitals Coventry and Warwickshire NHS TrustLondon, UK, 06 May 2026: Calla Lily Clinical Care, a wo
FUJIFILM Biosciences and NextCell launch new commercial platform comprised of RUO Stromal Cells and Cell Culture Media
Collaboration results in platform to help researchers overcome challenges in MSC research